Centessa Pharmaceuticals plc (CNTA)
Largest Insider Buys in Sector
CNTA Stock Price History Chart
CNTA Stock Performance
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Insider Activity of Centessa Pharmaceuticals plc
Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $11.08M worth of Centessa Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $4.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.
List of Insider Buy and Sell Transactions, Centessa Pharmaceuticals plc
| 2024-12-06 | Sale | Chief Executive Officer | 87,496 0.0665% | $18.46 | $1.62M | -1.55% | ||
| 2024-11-25 | Sale | Chief Executive Officer | 299 0.0002% | $18.23 | $5,451 | +1.73% | ||
| 2024-11-25 | Sale | Chief Business Officer | 10,000 0.0079% | $17.66 | $176,601 | +1.73% | ||
| 2024-11-22 | Sale | Chief Executive Officer | 1,671 0.0015% | $18.24 | $30,478 | +1.53% | ||
| 2024-11-21 | Sale | Chief Executive Officer | 3,511 0.0027% | $18.24 | $64,028 | -5.28% | ||
| 2024-11-20 | Sale | Chief Executive Officer | 55,000 0.0424% | $16.89 | $928,719 | +3.35% | ||
| 2024-11-13 | Sale | Chief Executive Officer | 32,023 0.0284% | $18.28 | $585,419 | -5.09% | ||
| 2024-10-25 | Sale | Chief Business Officer | 11,742 0.0103% | $15.38 | $180,628 | 0.00% | ||
| 2024-10-23 | Sale | Chief Executive Officer | 2,592 0.0023% | $15.32 | $39,697 | 0.00% | ||
| 2024-10-22 | Sale | Chief Executive Officer | 30,203 0.027% | $15.67 | $473,169 | 0.00% | ||
| 2024-10-21 | Sale | Chief Executive Officer | 22,205 0.0196% | $15.80 | $350,861 | +7.50% | ||
| 2024-09-25 | Sale | Chief Business Officer | 16,619 0.0148% | $15.69 | $260,724 | -0.12% | ||
| 2024-09-20 | Sale | Chief Executive Officer | 55,000 0.0484% | $16.53 | $908,985 | -2.80% | ||
| 2024-09-10 | Sale | Chief Executive Officer | 175,000 0.1752% | $16.52 | $2.89M | +10.70% | ||
| 2024-09-10 | Sale | Chief Business Officer | 30,000 0.0309% | $17.00 | $510,000 | +10.70% | ||
| 2024-09-09 | Sale | Chief Business Officer | 25,000 0.0222% | $15.00 | $375,000 | +7.94% | ||
| 2024-08-23 | Sale | Chief Executive Officer | 46,651 0.0395% | $12.30 | $573,905 | +24.44% | ||
| 2024-08-23 | Sale | Chief Business Officer | 17,802 0.015% | $12.29 | $218,792 | +24.44% | ||
| 2024-08-22 | Sale | Chief Executive Officer | 506 0.0004% | $12.23 | $6,188 | +31.07% | ||
| 2024-08-22 | Sale | Chief Business Officer | 12,198 0.0107% | $12.17 | $148,430 | +31.07% |
Insider Historical Profitability
| SAHA SAURABH | Chief Executive Officer | 575661 0.4372% | $18.18 | 3 | 15 | <0.0001% |
| Weinhoff Gregory M | Chief Business Officer | 183266 0.1392% | $18.18 | 1 | 9 | <0.0001% |
| Anderson Karen M. | Chief People Officer | 71525 0.0543% | $18.18 | 0 | 1 | |
| Rotman Harris | SVP Regulatory Affairs | 62625 0.0476% | $18.18 | 0 | 2 | |
| GAP (Bermuda) LTD | 10 percent owner | 9681818 7.3537% | $18.18 | 1 | 0 | <0.0001% |
| De Rubertis Francesco | director | 3936970 2.9903% | $18.18 | 6 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | 10 percent owner | 3936970 2.9903% | $18.18 | 6 | 0 | <0.0001% |
| GOYAL ARJUN | director | 3825659 2.9057% | $18.18 | 1 | 0 | <0.0001% |
| GRAINGER DAVID J | Chief Innovation Officer | 908575 0.6901% | $18.18 | 1 | 2 | <0.0001% |
| YVER ANTOINE | EVP & Chairman of Development | 783066 0.5948% | $18.18 | 0 | 17 | |
| CHAO DAVID M | Chief Administrative Officer | 222932 0.1693% | $18.18 | 1 | 2 | <0.0001% |
| Shahidi Javad | Chief Medical Officer | 158932 0.1207% | $18.18 | 0 | 2 | |
| HUSSAIN IQBAL J | General Counsel | 154712 0.1175% | $18.18 | 1 | 2 | <0.0001% |
| Templeman Thomas | Chief Technology Officer | 135792 0.1031% | $18.18 | 1 | 2 | <0.0001% |
| KANTOFF AARON | director | 60000 0.0456% | $18.18 | 1 | 0 | <0.0001% |
| Thorell Marella | Chief Accounting Officer | 1000 0.0008% | $18.18 | 1 | 0 | <0.0001% |
| Bush Tia L | Chief Quality Officer | 0 0% | $18.18 | 2 | 3 | <0.0001% |
Institutional Investor Ownership
| Medicxi Growth I Lp | $225.58M | 17.66 | 19.96M | 0% | +$0 | 50.22 | |
| General Atlantic | $109.4M | 8.57 | 9.68M | 0% | +$0 | 2.84 | |
| Ecor1 Capital Llc | $63.49M | 4.97 | 5.62M | 0% | +$0 | 0.45 | |
| Vida Ventures Advisors Llc | $44.43M | 3.48 | 3.93M | 0% | +$0 | 24.68 | |
| Perceptive Advisors | $34.84M | 2.73 | 3.08M | New | +$34.84M | 0.02 | |
| First Light Asset Management | $33.92M | 2.66 | 3M | New | +$33.92M | 2.86 | |
| T. Rowe Price | $33.43M | 2.62 | 2.96M | +16.48% | +$4.73M | <0.01 | |
| Fidelity Investments | $31.5M | 2.47 | 2.79M | 0% | +$0 | <0.01 | |
| Point72 Asset Management | $25.51M | 2 | 2.26M | +22.67% | +$4.71M | 0.04 | |
| Adage Capital Partners Gp L L C | $25.43M | 1.99 | 2.25M | -22.31% | -$7.3M | 0.05 | |
| Morgan Stanley | $24.15M | 1.89 | 2.14M | +76.05% | +$10.43M | <0.01 | |
| Octagon Capital Advisors LP | $23.28M | 1.82 | 2.06M | 0% | +$0 | 0.13 | |
| Tcg Crossover Management Llc | $23.06M | 1.81 | 2.04M | 0% | +$0 | 0.04 | |
| Artal Group S A | $15.96M | 1.25 | 1.41M | +39.51% | +$4.52M | 0.07 | |
| 5Am Venture Management Llc | $14.07M | 1.1 | 1.25M | New | +$14.07M | 0.95 | |
| Franklin Templeton Investments | $13.07M | 1.02 | 1.16M | +3.67% | +$462,237.80 | <0.01 | |
| Driehaus Capital Management LLC | $12.48M | 0.98 | 1.1M | +281.51% | +$9.21M | 0.12 | |
| American Century Investments | $10.43M | 0.82 | 923,120 | +5.41% | +$535,112.06 | 0.01 | |
| Affinity Asset Advisors | $9.39M | 0.74 | 830,546 | +4.38% | +$393,432.11 | 0.14 | |
| Tanager Wealth Management | $7.87M | 0.62 | 696,096 | 0% | +$0 | 1.49 | |
| Cormorant Asset Management Lp | $6.35M | 0.5 | 561,600 | 0% | +$0 | 0.3 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $5.48M | 0.43 | 485,174 | +27.32% | +$1.18M | 0.07 | |
| BlackRock | $4.32M | 0.34 | 382,462 | +10.45% | +$408,958.34 | <0.0001 | |
| ExodusPoint Capital Management, LP | $4.29M | 0.34 | 379,314 | +27.76% | +$931,382.46 | 0.05 | |
| Farallon Capital | $4.19M | 0.33 | 371,000 | New | +$4.19M | 0.03 | |
| PFM Health Sciences | $3.56M | 0.28 | 314,674 | New | +$3.56M | 0.1 | |
| Millennium Management LLC | $3.25M | 0.25 | 287,393 | +576.43% | +$2.77M | <0.01 | |
| Balyasny Asset Management Llc | $2.88M | 0.23 | 254,446 | New | +$2.88M | 0.01 | |
| Marshall Wace | $2.62M | 0.21 | 231,565 | New | +$2.62M | <0.01 | |
| Td Asset Management Inc | $2.58M | 0.2 | 228,644 | +22.72% | +$478,374.16 | <0.01 | |
| Renaissance Technologies | $2.47M | 0.19 | 218,800 | +17.89% | +$375,093.24 | <0.01 | |
| Ensign Peak Advisors Inc | $1.41M | 0.11 | 125,157 | 0% | +$0 | <0.01 | |
| The Manufacturers Life Insurance Company | $1.22M | 0.1 | 108,048 | +71.45% | +$508,804.93 | <0.01 | |
| Trexquant Investment LP | $1.09M | 0.09 | 96,531 | +572.5% | +$928,599.84 | 0.02 | |
| Landscape Capital Management | $1.02M | 0.08 | 90,240 | New | +$1.02M | 0.08 | |
| Two Sigma | $890,225.00 | 0.07 | 78,781 | +377.46% | +$703,775.06 | <0.01 | |
| Bank of America | $869,919.00 | 0.07 | 76,984 | +107.9% | +$451,480.10 | <0.0001 | |
| Cubist Systematic Strategies | $820,482.00 | 0.06 | 72,609 | +1,405.16% | +$765,970.78 | 0.01 | |
| Prelude Capital | $780,932.00 | 0.06 | 69,109 | New | +$780,932.00 | 0.06 | |
| Goldman Sachs | $621,805.00 | 0.05 | 55,027 | +122.5% | +$342,344.74 | <0.0001 | |
| Citadel Advisors LLC | $530,738.00 | 0.04 | 46,968 | -53.41% | -$608,346.34 | <0.0001 | |
| Geode Capital Management | $378,990.00 | 0.03 | 33,539 | 0% | +$0 | <0.0001 | |
| Jump Financial Llc | $371,465.00 | 0.03 | 32,873 | +129.88% | +$209,874.96 | <0.01 | |
| Rathbone Brothers | $353,690.00 | 0.03 | 31,300 | 0% | +$0 | <0.01 | |
| Acadian Asset Management | $330,000.00 | 0.03 | 29,409 | New | +$330,000.00 | <0.01 | |
| JPMorgan Chase | $308,095.00 | 0.02 | 27,265 | +156.49% | +$187,975.80 | <0.0001 | |
| Lynx1 Capital Management Lp | $196,620.00 | 0.02 | 17,400 | New | +$196,620.00 | 0.01 | |
| Gsa Capital Partners Llp | $154,000.00 | 0.01 | 13,587 | New | +$154,000.00 | 0.01 | |
| China Universal Asset Management Co., Ltd. | $122,232.00 | 0.01 | 10,817 | +69.17% | +$49,979.86 | 0.01 | |
| Qube Research & Technologies | $101,067.00 | 0.01 | 8,944 | +582.23% | +$86,252.73 | <0.0001 |